Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
CYNGN INC (CYN)
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
$0.27-19.01%
Close 2026-11-05 · 1-day change
NASDAQInformation TechnologySoftware - ApplicationSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CYN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage negative cash flow and capital allocation prudently | The company is actively managing capital despite negative cash flow. | Broken | cash flow worsens beyond -$8.4M after 2026-Q1 | Cash from operations: $-4.754M FY2026-Q2; GAAP. Published target: limit negative cash flow to no worse than -$8.4M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-4,754,150 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 17, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making growth business rather than an established compounder. Its multi-year view is on watch: momentum has weakened, recent financial performance trails its industry cohort, and management execution remains uneven.
The valuation model shows a premium versus peers, with optionality, or the possibility of future growth, driving the gap; confidence in that model is low. The evidence does not show exactly what the market expects, but the premium sits alongside losses and weak recent performance, leaving little clear evidence of a valuation cushion.
Near term, revenue rose from Q1 to Q2 2026 and was higher than in Q2 2025, but management said commercial execution was delayed relative to expectations. Costs and expenses for the first half of 2026 were higher than a year earlier despite restructuring actions, and the latest evidence flags repeated misses as a risk at the next report. The October legal and regulatory events, including a notice of delisting or failure, add uncertainty; the snapshot does not provide details on their impact.
The multi-year thesis hinges on whether enterprise deployments and commercial execution improve while costs come under control. Near-term, easier interest rates and steadier results from large technology companies could support the sector backdrop, while GDP growth below 2% could weigh more heavily on growth-sensitive technology names. The legal and listing events and the chair transition also need clarification; evidence on their effects is thin.
Over the next 1 to 3 years, CYN’s thesis depends on turning revenue growth into more reliable commercial delivery and cost control, while resolving substantial execution and listing uncertainty. The evidence remains weak and the valuation premium is supported by low-confidence growth optionality. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce operating losses and improve efficiency |
| Operating losses improved from -$8.4M to -$6.9M in the same period. |
| Broken |
| operating loss worsens beyond -$8.4M after 2026-Q1 |
Operating income: $-6.754M FY2026-Q2; GAAP. Published target: operating loss better than -$6.9M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026-6,754,003 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth through product and market expansion | A primary condition in CYNGN INC's published investment case. The stated target is >= $104.6K revenue in 2026-Q1. | Broken | revenue falls below $33.7K in any quarter after 2026-Q1 | Revenue: $144,459 FY2026-Q2; GAAP. Published target: >= $104.6K revenue in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 13, 2026144,459 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Unavailable → $-1.46 · observed estimates
Unavailable → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | Unavailable | Unavailable | — / 0 |
| 2026-07-25 | Unavailable | Unavailable | — / 0 |
| 2026-07-26 | Unavailable | Unavailable | — / 0 |
| 2026-07-27 | Unavailable | Unavailable | — / 0 |
| 2026-07-28 | Unavailable | Unavailable | — / 0 |
| 2026-07-29 | Unavailable | Unavailable | — / 0 |
| 2026-07-30 | Unavailable | Unavailable | — / 0 |
| 2026-07-31 | Unavailable | Unavailable | — / 0 |
| 2026-08-01 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-02 | Unavailable | Unavailable | — / 0 |
| 2026-08-03 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-04 | Unavailable | Unavailable | — / 0 |
| 2026-08-05 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-06 | Unavailable | Unavailable | — / 0 |
| 2026-08-07 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-08 | Unavailable | Unavailable | — / 0 |
| 2026-08-09 | Unavailable | Unavailable | — / 0 |
| 2026-08-10 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-11 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-12 | Unavailable | Unavailable | — / 0 |
| 2026-08-13 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-14 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-15 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-16 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-17 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-18 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-19 | $316.50 | $33,560,000 | 1 / 1 |
| 2026-08-20 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-21 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-22 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-23 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-24 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-25 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-26 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-27 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-28 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-29 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-30 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-08-31 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-01 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-02 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-03 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-04 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-05 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-06 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-07 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-08 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-09 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-10 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-11 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-12 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-13 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-14 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-15 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-16 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-17 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-18 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-19 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-20 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-21 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-22 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-23 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-24 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-25 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-26 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-27 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-28 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-29 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-09-30 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-01 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-02 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-03 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-04 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-05 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-06 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-07 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-08 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-09 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-10 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-11 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-12 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-13 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-14 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-15 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-16 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-17 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-18 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-19 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-20 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-21 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-22 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-23 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-24 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-25 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-26 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-27 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-28 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-29 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-30 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-10-31 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-11-01 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-11-02 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-11-03 | $-1.46 | $8,000,000 | 1 / 1 |
| 2026-11-04 | $-1.46 | $8,000,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.